Browsing: NSCLC

Does accelerated treatment (60 Gy in 25 fractions) improve outcomes for stage III non-small cell lung cancer (NSCLC)? KROG 0903…

Headline: We now have phase 3 data comparing stereotactic body radiation (SBRT) to hypofractionated radiation (HFRT) for stage I non-small…

Headline: Consolidative ablative radiation for oligoprogressive non-small cell lung cancer (NSCLC) corresponds to a 4-fold benefit in progression-free survival with…

We’ve seen several studies identifying several substructures in the heart that are associated with worse survival or more cardiac events…

The LungART trial showed that adjuvant radiation does not improve disease-free survival in patients with resected, N2 NSCLC. More recently,…

Top Line: CheckMate 816 established the benefit of adding nivolumab to neoadjuvant chemo for resectable non-small cell lung cancer (NSCLC).…

In this German retrospective study, 62 patients receiving adjuvant brain radiation and immune checkpoint inhibition following resection of non-small cell…

Patients with higher PD-L1 expression derive greater benefit from immunotherapy. So, how does that affect patients with stage III NSCLC…

Top Line: What is the risk of bronchial stenosis after 7.5 Gy x 8 for central NSCLC? The Study: This…

Maintenance durvalumab after chemoradiation (CRT) for stage III NSCLC improves median survival 18.4 months and 5-year overall survival by 9.8%.…